267 related articles for article (PubMed ID: 24762683)
41. Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: a multicentre study.
Zullo A; De Francesco V; Scaccianoce G; Manes G; Efrati C; Hassan C; Maconi G; Piglionica D; Cannaviello C; Panella C; Morini S; Ierardi E
Dig Liver Dis; 2007 Sep; 39(9):806-10. PubMed ID: 17644057
[TBL] [Abstract][Full Text] [Related]
42. Quadruple therapy for eradication of Helicobacter pylori.
Ma HJ; Wang JL
World J Gastroenterol; 2013 Feb; 19(6):931-5. PubMed ID: 23429422
[TBL] [Abstract][Full Text] [Related]
43. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
[TBL] [Abstract][Full Text] [Related]
44. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options.
Sanches B; Coelho L; Moretzsohn L; Vieira G
Helicobacter; 2008 Dec; 13(6):572-6. PubMed ID: 19166424
[TBL] [Abstract][Full Text] [Related]
45. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease.
Malekzadeh R; Ansari R; Vahedi H; Siavoshi F; Alizadeh BZ; Eshraghian MR; Vakili A; Saghari M; Massarrat S
Aliment Pharmacol Ther; 2000 Mar; 14(3):299-303. PubMed ID: 10735922
[TBL] [Abstract][Full Text] [Related]
46. Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen.
Sotoudehmanesh R; Malekzadeh R; Vahedi H; Dariani NE; Asgari AA; Massarrat S
Digestion; 2001; 64(4):222-5. PubMed ID: 11842278
[TBL] [Abstract][Full Text] [Related]
47. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
48. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients.
Qasim A; Sebastian S; Thornton O; Dobson M; McLoughlin R; Buckley M; O'Connor H; O'Morain C
Aliment Pharmacol Ther; 2005 Jan; 21(1):91-6. PubMed ID: 15644050
[TBL] [Abstract][Full Text] [Related]
49. Vonoprazan on the Eradication of Helicobacter pylori Infection.
Huang J; Lin Y
Turk J Gastroenterol; 2023 Mar; 34(3):221-226. PubMed ID: 36511603
[TBL] [Abstract][Full Text] [Related]
50. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
[TBL] [Abstract][Full Text] [Related]
51. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
[TBL] [Abstract][Full Text] [Related]
52. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea.
Kim BG; Lee DH; Ye BD; Lee KH; Kim BW; Kim SG; Kim SW; Kim SK; Kim JJ; Kim HY; Park JJ; Park CY; Baik GH; Lee YC; Lee JH; Lee JH; Chun HJ; Hahm KB; Hong SJ; Lee SW; Jung HC
Helicobacter; 2007 Feb; 12(1):31-5. PubMed ID: 17241298
[TBL] [Abstract][Full Text] [Related]
53. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.
Georgopoulos S; Papastergiou V; Xirouchakis E; Laoudi F; Lisgos P; Spiliadi C; Papantoniou N; Karatapanis S
J Clin Gastroenterol; 2013 Mar; 47(3):228-32. PubMed ID: 22858517
[TBL] [Abstract][Full Text] [Related]
54. Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing.
Forné M; Viver JM; Esteve M; Fernández-Bañares F; Lite J; Espinós JC; Quintana S; Salas A; Garau J
Am J Gastroenterol; 1998 Jan; 93(1):35-8. PubMed ID: 9448170
[TBL] [Abstract][Full Text] [Related]
55. [Quadruple regimens using domestically manufactured drugs in gastritis and duodenal ulcer patients for Helicobacter pylori eradication: a perspective, multicenter, randomized controlled trial].
Gao W; Hu F; Cheng H; Wang H; Yang Y; Liang H; Zhang S; Meng F; Cui M; Wei H; Sheng J; An HJ; Jiang B; Chen Y; Li Y; Zuo X; Gong J; Zhao P; Dong L; Wang B; Jiang K; Zhang G; Li J; Zhao Y; Gao H; Yang L
Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(4):260-4. PubMed ID: 26879784
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment.
Sacco F; Spezzaferro M; Amitrano M; Grossi L; Manzoli L; Marzio L
Dig Liver Dis; 2010 Feb; 42(2):110-4. PubMed ID: 19846355
[TBL] [Abstract][Full Text] [Related]
57. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Dore MP; Farina V; Cuccu M; Mameli L; Massarelli G; Graham DY
Helicobacter; 2011 Aug; 16(4):295-300. PubMed ID: 21762269
[TBL] [Abstract][Full Text] [Related]
58. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
[TBL] [Abstract][Full Text] [Related]
59. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy.
Kim SY; Lee SW; Hyun JJ; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Choi JH
J Clin Gastroenterol; 2013 Jan; 47(1):21-4. PubMed ID: 22647826
[TBL] [Abstract][Full Text] [Related]
60. Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China.
Wang L; Lin Z; Chen S; Li J; Chen C; Huang Z; Ye B; Ding J; Li W; Wu L; Jiang Y; Meng L; Du Q; Si J
Clin Microbiol Infect; 2017 Jun; 23(6):391-395. PubMed ID: 28077338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
